Phase I study of high-dose piroxantrone with granulocyte colony-stimulating factor.

Abstract

The use of G-CSF results in a more than twofold increase in the MTD of piroxantrone. However, symptomatic cardiotoxicity is prominent, especially in patients who have received prior treatment with anthracyclines.